1 ANNEX, Decision_act (EU) 2002/364

In forcesince 2 Mar 2021

The common technical specifications set out in this Annex shall apply for the purposes of Annex II List A to Directive 98/79/EC.

The probability that the device gives a positive result in the presence of the target marker.

A specimen known to be positive for the target marker and correctly classified by the device.

A specimen known to be positive for the target marker and misclassified by the device.

The probability that the device gives a negative result in the absence of the target marker.

A specimen known to be negative for the target marker and misclassified by the device.

A specimen known to be negative for the target marker and correctly classified by the device.

Analytical sensitivity may be expressed as the limit of detection, i.e. the smallest amount of the target marker that can be precisely detected.

Analytical specificity means the ability of the method to determine solely the target marker.

The term ‘NAT’ is used for tests for the detection and/or quantification of nucleic acids by either amplification of a target sequence, by amplification of a signal or by hybridisation.

‘Rapid test’ means qualitative or semi-quantitative in vitro diagnostic medical devices, used singly or in a small series, which involve non-automated procedures and have been designed to give a fast result.

The robustness of an analytical procedure means the capacity of an analytical procedure to remain unaffected by small but deliberate variations in method parameters and provides an indication of its reliability during normal usage.

The whole system failure rate means the frequency of failures when the entire process is performed as prescribed by the manufacturer.

First-line assay means an assay used to detect a marker or analyte, and which may be followed by a confirmatory assay. Devices intended solely to be used to monitor a previously determined marker or analyte are not considered first-line assays.

Confirmatory assay means an assay used for the confirmation of a reactive result from a first-line assay.

Virus typing assay means an assay used for typing with already known positive samples, not used for primary diagnosis of infection or for screening.

Sero-conversion HIV samples mean:

p24 antigen and/or HIV RNA positive, and

recognised by all of the antibody screening tests, and

positive or indeterminate confirmatory assays.

Early seroconversion HIV samples mean:

p24 antigen and/or HIV RNA positive, and

not recognised by all of the antibody screening tests, and

indeterminate or negative confirmatory assays.

3.1.1.

Devices which detect virus infections shall meet the requirements for sensitivity and specificity set out in Table 1, Table 3, Table 4 and Table 5, which apply to them taking account of the intended purpose of the devices concerned, virus type and entities to be detected (antigen and/or antibody). See also principle 3.1.11 for first-line assays.

3.1.2.

Devices intended by the manufacturer for testing body fluids other than serum or plasma, e.g. urine, saliva, etc., shall meet the same CTS requirements for sensitivity and specificity as serum or plasma tests. The performance evaluation shall test samples from the same individuals in both the tests to be approved and in a respective serum or plasma assay.

3.1.3.

Devices for self-testing shall meet the same CTS requirements for sensitivity and specificity as respective devices for professional use. Relevant parts of the performance evaluation shall be carried out (or repeated) by appropriate lay users to validate the operation of the device and the instructions for use. The lay users selected for the performance evaluation shall be representative of the intended users groups.

Performance evaluation of a device for self-testing shall include, for each body fluid claimed for use with the device, e.g. whole blood, urine, saliva, etc., at least 200 lay users that are known positive for the infection and at least 400 lay users that do not know their status, of which at least 200 are at high risk of acquiring the infection. The sensitivity and specificity of the device for self-testing in the hands of lay users shall be defined against the confirmed patient infectious status.

3.1.4.

All performance evaluations shall be carried out in direct comparison with an established state-of-the-art device. The device used for comparison shall be one bearing CE marking, if on the market at the time of the performance evaluation.

3.1.5.

If discrepant test results are identified as part of an evaluation, these results shall be resolved as far as possible, for example:

by evaluation of the discrepant sample in further test systems,

by use of an alternative method or marker,

by a review of the clinical status and diagnosis of the patient, and

by the testing of follow-up-samples.

3.1.6.

Performance evaluations shall be performed on a population equivalent to the European population.

3.1.7.

Positive specimens used in the performance evaluation shall be selected to reflect different stages of the respective disease(s), different antibody patterns, different genotypes, different subtypes, mutants, etc.

3.1.8.

Sensitivity with true positives and sero-conversion samples shall be evaluated as follows:

3.1.8.1. Diagnostic test sensitivity during sero-conversion has to represent the state of the art. Whether further testing of the same or additional sero-conversion panels is conducted by the notified body or by the manufacturer the results shall confirm the initial performance evaluation data (see Table 1). Sero-conversion panels should start with a negative bleed(s) and should have narrow bleeding intervals.

3.1.8.2. For blood screening devices (with the exception of HBsAg and anti-HBc tests), all true positive samples shall be identified as positive by the device to be CE marked (Table 1). For HBsAg and anti-HBc tests the new device shall have an overall performance at least equivalent to that of the established device (see 3.1.4).

3.1.8.3. Regarding HIV tests:

all sero-conversion HIV samples shall be identified as positive, and

at least 40 early sero-conversion HIV samples shall be tested. Results should conform to the state of the art.

3.1.9.

Performance evaluation of first line assays shall include 25 positive (if available in the case of rare infections) ‘same day’ fresh serum samples (≤ 1 day after sampling).

3.1.10.

Negative specimens used in a performance evaluation shall be defined so as to reflect the target population for which the test is intended, for example blood donors, hospitalised patients, pregnant women, etc.

3.1.11.

For performance evaluations for first line assays (Table 1 and Table 3) blood donor populations shall be investigated from at least two blood donation centers and consist of consecutive blood donations, which have not been selected to exclude first time donors.

3.1.12.

Devices shall have a specificity of at least 99,5 % on blood donations, unless otherwise indicated in the accompanying tables. Specificity shall be calculated using the frequency of repeatedly reactive (i.e. false positive) results in blood donors negative for the target marker.

3.1.13.

Devices shall be evaluated to establish the effect of potential interfering substances, as part of the performance evaluation. The potential interfering substances to be evaluated will depend to some extent on the composition of the reagent and configuration of the assay. Potential interfering substances shall be identified as part of the risk analysis required by the essential requirements for each new device but may include, for example:

specimens representing ‘related’ infections,

specimens from multipara, i.e. women who have had more than one pregnancy, or rheumatoid factor positive patients,

for recombinant antigens, human antibodies to components of the expression system, for example anti-E. coli, or anti-yeast.

3.1.14.

For devices intended by the manufacturer to be used with serum and plasma the performance evaluation must demonstrate serum to plasma equivalency. This shall be demonstrated for at least 50 donations (25 positive and 25 negative).

3.1.15.

For devices intended for use with plasma the performance evaluation shall verify the performance of the device using all anticoagulants which the manufacturer indicates for use with the device. This shall be demonstrated for at least 50 donations (25 positive and 25 negative).

3.1.16.

As part of the required risk analysis the whole system failure rate leading to false-negative results shall be determined in repeat assays on low-positive specimens.

3.1.17.

If a new in vitro diagnostic medical device belonging to Annex II List A is not specifically covered by the common technical specification, the common technical specification for a related device should be taken into account. Related devices may be identified on different grounds, e.g. by the same or similar intended use or by similar risks.

3.2.1.

HIV antigen and antibody combined tests intended for the detection of HIV-1 p24 antigen and HIV-1/2 antibody shall meet the requirements for sensitivity and specificity set out in Table 1 and Table 5.

3.2.2.

Hepatitis C virus (HCV) antigen and antibody combined tests intended for the detection of HCV antigen and HCV antibody shall meet the requirements for sensitivity and specificity set out in Table 1 and Table 5. HCV seroconversion panels for the evaluation of HCV antigen and antibody combined tests shall start with one or more negative bleeds and comprise panel members from early HCV infection (HCV core antigen and/or HCV RNA positive but anti-HCV negative). HCV antigen and antibody combined tests shall demonstrate enhanced sensitivity in early HCV infection when compared to HCV antibody only tests.

The performance evaluation criteria for NAT assays can be found in Table 2.

3.3.1.

For target sequence amplification assays, a functionality control for each test sample (internal control) shall reflect the state of the art. This control shall as far as possible be used throughout the whole process, i.e. extraction, amplification/hybridisation, detection.

3.3.2.

The analytical sensitivity or detection limit for NAT assays shall be expressed by the 95 % positive cut-off value. This is the analyte concentration where 95 % of test runs give positive results following serial dilutions of an international reference material, where available, such as a World Health Organisation (WHO) International Standard or reference material calibrated against a WHO International Standard.

3.3.2a.

Qualitative HIV NAT assays intended to be used to detect the presence of HIV in blood, blood components, cells, tissues or organs, or in any of their derivatives, in order to assess their suitability for transfusion, transplantation or cell administration shall be designed to detect both HIV-1 and HIV-2.

3.3.2b.

Qualitative HIV NAT assays, other than virus typing assays, shall be designed to compensate for the potential failure of a HIV-1 NAT target region, e.g. by using two independent target regions.

3.3.3.

Genotype detection shall be demonstrated by appropriate primer or probe design validation and shall also be validated by testing characterised genotyped samples.

3.3.4.

Results of quantitative NAT assays shall be traceable to international standards or calibrated reference materials, if available, and be expressed in international units utilised in the specific field of application.

3.3.5.

NAT assays may be used to detect virus in antibody negative samples, i.e. pre-sero-conversion samples. Viruses within immune-complexes may behave differently in comparison to free viruses, for example during a centrifugation step. It is therefore important that during robustness studies, antibody-negative (pre-sero-conversion) samples are included.

3.3.6.

For investigation of potential carry-over, at least five runs with alternating high-positive and negative specimens shall be performed during robustness studies. The high positive samples shall comprise samples with naturally occurring high virus titres.

3.3.7.

The whole system failure rate leading to false-negative results shall be determined by testing low-positive specimens. Low-positive specimens shall contain a virus concentration equivalent to three times the 95 % positive cut-off virus concentration.

3.4.1.

The manufacturer’s release testing criteria shall ensure that every batch consistently identifies the relevant antigens, epitopes, and antibodies.

3.4.2.

The manufacturer’s batch release testing for first line assays shall include at least 100 specimens negative for the relevant analyte.

Criteria for performance evaluation of reagents and reagent products for determining the blood groups antigens: ABO blood group system ABO1 (A), ABO2 (B), ABO3 (A,B); Rh blood group system RH1 (D), RH2 (C), RH3 (E), RH4 (c), RH5 (e); Kell blood group system KEL1 (K) can be found in Table 9.

3.5.1.

All performance evaluations shall be carried out in direct comparison with an established state-of-the-art device. The device used for comparison shall be one bearing CE marking, if on the market at the time of the performance evaluation.

3.5.2.

If discrepant test results are identified as part of an evaluation, these results shall be resolved as far as possible, for example:

by evaluation of the discrepant sample in further test systems,

by use of an alternative method,

3.5.3.

Performance evaluations shall be performed on a population equivalent to the European population.

3.5.4.

Positive specimens used in the performance evaluation shall be selected to reflect variant and weak antigen expression.

3.5.5.

Devices shall be evaluated to establish the effect of potential interfering substances, as part of the performance evaluation. The potential interfering substances to be evaluated will depend to some extent on the composition of the reagent and configuration of the assay. Potential interfering substances shall be identified as part of the risk analysis required by the essential requirements for each new device.

3.5.6.

For devices intended for use with plasma the performance evaluation shall verify the performance of the device using all anticoagulants which the manufacturer indicates for use with the device. This shall be demonstrated for at least 50 donations.

3.6.1.

The manufacturer’s release testing criteria shall ensure that every batch consistently identifies the relevant antigens, epitopes, and antibodies.

3.6.2.

Requirements for manufacturers batch release testing are outlined in Table 10.

CTS for Variant Creutzfeldt-Jakob disease (vCJD) assays for blood screening are set out in Table 11.

anti-HIV 1/2, HIV 1/2 Ag/Ab | Anti-HTLV-I/II | anti-HCV, HCV Ag/Ab | HBsAg | Anti-HBc

Diagnostic sensitivity | Positive specimens |

400 HIV-1

100 HIV-2

including 40 non-B-subtypes, all available HIV/1 subtypes shall be represented by at least 3 samples per subtype

300 HTLV-I

100 HTLV-II

400 (positive samples)

Including samples from different stages of infection and reflecting different antibody patterns.

Genotype 1-4: > 20 samples per genotype (including non-a subtypes of genotype 4);

5: > 5 samples;

6: if available

400

including subtype-consideration

400

including evaluation of other HBV-markers

Sero-conversion panels |

20 panels

10 further panels (at notified body or manufacturer)

To be defined when available |

20 panels

10 further panels (at notified body or manufacturer)

20 panels

10 further panels (at notified body or manufacturer)

To be defined when available

Analytical sensitivity | Standards | | | | 0,130 IU/ml ( WHO International Standard: Third International Standard for HBsAg, subtypes ayw1/adw2, HBV genotype B4, NIBSC code: 12/226) |

Specificity | Unselected donors (including first-time donors) | 5000 | 5000 | 5000 | 5000 | 5000

Hospitalized patients | 200 | 200 | 200 | 200 | 200

Potentially cross-reacting blood-specimens (RF+, related viruses, pregnant women, etc) | 100 | 100 | 100 | 100 | 100

[European Pharmacopoeia guideline.]

Notes: Acceptance criteria for ‘whole system failure rate leading to false-neg results’ is 99/100 assays positive.

For quantitative NATs a study shall be performed on at least 100 positive specimens reflecting the routine conditions of users (e.g. no pre-selection of specimens). Comparative results with another NAT test system shall be generated in parallel.

For qualitative NATs a study on diagnostic sensitivity shall be performed using at least 10 sero-conversion panels. Comparative results with another NAT test system shall be generated in parallel.

HIV1 | HCV | HBV | HTLV I/II | Acceptance criteria

NAT | qualitative | quantitative | qualitative | quantitative | qualitative | quantitative | qualitative | quantitative

As for HIV quantitative | As for HIV quantitative | As for HIV quantitative

Sensitivity

Detection limit

Detection of analytical sensitivity (IU/ml; defined on WHO standards or calibrated reference materials)

According to EP validation guideline: several dilution series into borderline concentration; statistical analysis (e.g. Probit analysis) on the basis of at least 24 replicates; calculation of 95 % cut-off value | Detection limit: as for qualitative tests; Quantification limit: dilutions (half-log10 or less) of calibrated reference preparations, definition of lower, upper quantification limit, precision, accuracy, ‘linear’ measuring range, ‘dynamic range’. Reproducibility at different concentration levels to be shown | According to EP validation guideline: several dilution series into borderline concentration; statistical analysis (e.g. Probit analysis) on the basis of at least 24 replicates; calculation of 95 % cut-off value | | According to EP validation guideline: several dilution series into borderline concentration; statistical analysis (e.g. Probit analysis) on the basis of at least 24 replicates; calculation of 95 % cut-off value | | According to EP validation guideline: several dilution series into borderline concentration; statistical analysis (e.g. Probit analysis) on the basis of at least 24 replicates; calculation of 95 % cut-off value | |

Genotype/subtype detection/quantification efficiency | At least 10 samples per subtype (as far as available) | Dilution series of all relevant genotypes/subtypes, preferably of reference materials, as far as available | At least 10 samples per genotype (as far as available) | | As far as calibrated genotype reference materials are available | | As far as calibrated genotype reference materials are available | |

Cell culture supernatants (could substitute for rare HIV-1 subtypes) | Transcripts or plasmids quantified by appropriate methods may be used. | | | | | | |

According to EP validation guideline as far as calibrated subtype reference materials are available; in vitro transcripts could be an option | | According to EP validation guideline as far as calibrated subtype reference materials are available; in vitro transcripts could be an option | | According to EP validation guideline as far as calibrated subtype reference materials are available; in vitro transcripts could be an option | | According to EP validation guideline as far as calibrated subtype reference materials are available; in vitro transcripts could be an option | |

Diagnostic specificity negative samples | 500 blood donors | 100 blood donors | 500 blood donors | | 500 blood donors | | 500 individual blood donations | |

Potential cross-reactive markers | By suitable assay design evidence (e.g. sequence comparison) and/or testing of at least 10 human retrovirus (e.g. HTLV)-positive samples | As for qualitative tests | By assays design and/or testing of at least 10 human flavivirus (e.g. HGV, YFV) positive samples | | By assays design and/or testing of at least 10 other DNA-virus positive samples | | By assay design and/or testing of at least 10 human retrovirus (e.g. HIV-) positive samples | |

Robustness | | As for qualitative tests | | | | | | |

Cross-contamination | At least 5 runs using alternating high positive (known to occur naturally) and negative samples | | At least 5 runs using alternating high positive (known to occur naturally) and negative samples | | At least 5 runs using alternating high positive (known to occur naturally) and negative samples | | At least 5 runs using alternating high positive (known to occur naturally) and negative samples | |

Inhibition | Internal control preferably to go through the whole NAT procedure | | Internal control preferably to go through the whole NAT procedure | | Internal control preferably to go through the whole NAT procedure | | Internal control preferably to go through the whole NAT procedure | |

Whole system failure rate leading to false-neg results | At least 100 samples virus-spiked with 3 × the 95 % pos cut-off concentration | | At least 100 samples virus-spiked with 3 × the 95 % pos cut-off concentration | | At least 100 samples virus-spiked with 3 × the 95 % pos cut-off concentration | | At least 100 samples virus-spiked with 3 × the 95 % pos cut-off concentration | | 99/100 assays positive

anti-HIV 1/2, HIV 1/2 Ag/Ab | anti-HCV, HCV Ag/Ab | HBsAg | anti-HBc | anti-HTLV I and II | Acceptance criteria

Diagnostic sensitivity | Positive specimens | Same criteria as in Table 1 | Same criteria as in Table 1 | Same criteria as in Table 1 | Same criteria as in Table 1 | Same criteria as in Table 1 | Same criteria as in Table 1

Sero-conversion panels | Same criteria as in Table 1 | Same criteria as in Table 1 | Same criteria as in Table 1 | Same criteria as in Table 1 | Same criteria as in Table 1 | Same criteria as in Table 1

Diagnostic specificity | Negative specimens | 21 000 blood donations | 1000 blood donations | 1000 blood donations | 1000 blood donations | 1000 blood donations |

≥ 99 %

(anti-HBc: ≥ 96 %)

200 clinical specimens | 200 clinical specimens | 200 clinical specimens | 200 clinical specimens | 200 clinical specimens

200 samples from pregnant women | 200 samples from pregnant women | 200 samples from pregnant women | | 200 samples from pregnant women

100 potentially interfering samples | 100 potentially interfering samples | 100 potentially interfering samples | 100 potentially interfering samples | 100 potentially interfering samples

[Acceptance criteria: no neutralisation for HBsAg confirmatory assay.]

anti-HIV 1/2, HIV 1/2 Ag/Ab confirmatory assays | anti-HTLV I and II confirmatory assays | anti-HCV, HCV Ag/Ab supplementary assays | HBsAg confirmatory assays | Acceptance criteria

Diagnostic sensitivity | Positive specimens |

200 HIV-1 and 100 HIV-2

Including samples from different stages of infection and reflecting different antibody patterns

200 HTLV-I and 100 HTLV-II |

300 HCV (positive samples)

Including samples from different stages of infection and reflecting different antibody patterns.

Genotypes 1 – 4: > 20 samples (including non-a subtypes of genotype 4;

Genotype 5: > 5 samples;

Genotype 6: if available

300 HBsAg

This article is long: the rest is at the official publication.

  • celex=31998L0079